The Russian human adenovirus-based vaccine trials in the UAE have completed the inoculation phase, with 1,000 volunteers receiving their second dose.
The trials have moved into the scientific data collection phase, with UAE findings to be combined with existing global research findings and interim results to be released by April 2021. The Russian vaccine has so far shown an efficacy rate of 91.6 per cent.
